Table 3.
The patents of anti-VEGF antibody biosimilar.
| Patent | Title | Legal status |
|---|---|---|
| CN201110274419.2 | Simple and convenient chemical industrial technology for prokaryotic expression and purification of humanized anti-vascular endothelial growth factor monoclonal recombinant antibody | Deemed withdrawal |
| CN201210185573.7 | Method for purifying and preparing anti-VEGF antibody fragment | Licensing |
| CN201210579417.9 | Preparation method of long-acting sustained-release microspheres containing bevacizumab | Deemed withdrawal |
| CN201310337426.1 | Bevacizumab eye drop and preparation method thereof | Licensing |
| CN201410093781.3 | Hypodermic high-density anti-VEGF antibody formulation | Licensing |
| CN201410198778.8 | High-stability humanized antibody preparation for treating VEGF related diseases | Substantive examination |
| CN201410487742.1 | Pharmaceutical composition of humanized antibody for vascular endothelial growth factor | Substantive examination |
| CN201410625267.X | Biological activity detection method for VEGF targeted therapy drugs | Deemed withdrawal |
| CN201410757524.5 | Stable anti-VEGF antibody preparation and application thereof | Licensing |
| CN201510583416.5 | Stable protein preparation | Deemed withdrawal |
| CN201610244018.5 | Stable anti-VEGF (vascular endothelial growth factor) antibody preparation and application thereof | Rejection |
| CN201610817744.1 | Purification method of anti-VEGF (Vascular Endothelial Growth Facto) type monoclonal antibody | Substantive examination |
| CN201611216530.5 | Stable bevacizumab preparation | Deemed withdrawal |
| CN201710716867.0 | Method for preparing highly-pure ranibizumab inclusion body | Deemed withdrawal |
| CN201810364192.2 | High-producing strain with capability of efficient secretion expression of anti-VEGF-Fab antibody fragment, and construction method thereof | Substantive examination |
| CN201810355289.7 | Method for efficient expression of antibody Fab fragments | Substantive examination |
| CN201810998933.2 | Monoclonal antibody for neutralizing bevacizumab and application thereof | Licensing |
| CN201811563705.9 | Purification method of proteins | Application publication |
| CN201911417826.7 | Biological activity analysis method of recombinant anti-VEGFR2 monoclonal antibody and application thereof | Substantive examination |